What evidence is there to suggest a possibility of harm with bempedoic acid?
Evidence suggests a possibility of harm with bempedoic acid, with a non-significant trend toward higher CV (0.4% versus 0.1%) and all-cause mortality (0.9% versus 0.3%) in the treatment group compared to the placebo group. Adverse effects of bempedoic acid include potentially increased incidence of muscle pain (p=0.05) and gout (p <0.03), but with lower rates of new- onset or worsening DM (p=0.02).